The findings of the present study indicate that the use of surrogate markers as primary endpoints should be clearly stated as such in the abstracts of the trials, in order not to overestimate the potential clinical benefit for the individual patients.
![[This page as RDF]](http://data.gesis.org/somesci/static/rdf-icon.gif){kind=icon}